Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 Febbraio;55(1) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 Febbraio;55(1):57-65

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 Febbraio;55(1):57-65

 ORIGINAL ARTICLES

Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive 131I whole body scan?

Piccardo A. 1, Foppiani L. 2, Morbelli S. 1, Bianchi P. 1, Barbera F. 1, Biscaldi E. 3, Altrinetti V. 1, Villavecchia G. 1, Cabria M. 1

1 Department of Nuclear Medicine, Galliera Hospital, Genoa, Italy;
2 Department of Endocrinology, Galliera Hospital, Genoa, Italy;
3 Department of Radiology, Galliera Hospital, Genoa, Italy

AIM: Stage-IV differentiated thyroid cancer (DTC) patients may present elevated serum thyroglobulin (Tg) levels associated with positive [131I] whole-body-scan (WBS). Nevertheless some patients in whom WBS does not reveal new sites of disease show increased Tg levels. This finding prompts thorough restaging in order to exclude the presence of metastases unable to concentrate iodine. The aim of our study was to evaluate the impact of [18F]FDG-PET/CT in both the assessment of overall extent of the disease and the therapeutic management in a group of stage-IV DTC patients.
METHODS: On suspicious of non-iodine concentrating additional metastases, 20 stage-IV DTC patients with increasing Tg levels and stable positive post-therapy WBS were enrolled. Conventional imaging (CI) procedures, including neck ultrasonography, bone-scintigraphy and computed tomography (CT) were performed before [18F]FDG-PET/CT.
RESULTS: [18F]FDG-PET/CT was positive in 16 out of 20 patients (80%). In 9 patients (45%) [18F]FDG PET/CT detected a larger number of tumour recurrences/metastatic sites than WBS+CI. [18F]FDG PET/CT findings prompted modification of the management of 11 patients (55%), in whom surgery or external radiotherapy were eventually considered more appropriate than radioactive iodine therapy. These further therapies improved the quality of life in several patients but did not change their survival rate.
CONCLUSION: Our results showed that [18F]FDG-PET/CT can detect new radioiodine-negative metastases in advanced DTC patients with unchanged positive WBS and increasing Tg levels. [18F]FDG-PET/CT may constitute a useful tool in the choice of the best therapeutic strategy in such difficult cases.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina